Ontology highlight
ABSTRACT: Background
Postoperative recovery after live donor nephrectomy is largely determined by the consequences of postoperative pain and analgesia consumptions. The use of deep neuromuscular blockade has been shown to reduce postoperative pain scores after laparoscopic surgery. In this study, we will investigate whether deep neuromuscular blockade also improves the early quality of recovery after live donor nephrectomy.Methods
The RELAX-study is a phase IV, multicenter, double-blinded, randomized controlled trial, in which 96 patients, scheduled for living donor nephrectomy, will be randomized into two groups: one with deep and one with moderate neuromuscular blockade. Deep neuromuscular blockade is defined as a post-tetanic count of 1-2. Our primary outcome measurement will be the Quality of Recovery-40 questionnaire (overall score) at 24 h after extubation.Discussion
This study is, to our knowledge, the first randomized study to assess the effectiveness of deep neuromuscular blockade during laparoscopic donor nephrectomy in enhancing postoperative recovery. The study findings may also be applicable for other laparoscopic procedures.Trial registration
clinicaltrials.gov, NCT02838134 . Registered on 29 June 2016.
SUBMITTER: Bruintjes MH
PROVIDER: S-EPMC5336688 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Bruintjes Moira H D MH Braat Andries E AE Dahan Albert A Scheffer Gert-Jan GJ Hilbrands Luuk B LB d'Ancona Frank C H FC Donders Rogier A R T RA van Laarhoven Cornelis J H M CJ Warlé Michiel C MC
Trials 20170304 1
<h4>Background</h4>Postoperative recovery after live donor nephrectomy is largely determined by the consequences of postoperative pain and analgesia consumptions. The use of deep neuromuscular blockade has been shown to reduce postoperative pain scores after laparoscopic surgery. In this study, we will investigate whether deep neuromuscular blockade also improves the early quality of recovery after live donor nephrectomy.<h4>Methods</h4>The RELAX-study is a phase IV, multicenter, double-blinded, ...[more]